^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FoundationFocus CDxBRCA Assay

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    Evidence Level:
    Sensitive: A1 - Approval

    [BRCA2 mutation-Ovarian Cancer-rucaparib]

    Source:
    FDA
    Test:

    BRACAnalysis CDx™, FoundationFocus CDxBRCA Assay

    Published date:
    12/19/2016
    Excerpt:
    RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
    Evidence Level:
    Sensitive: A1 - Approval

    [BRCA1 mutation-Ovarian Cancer-rucaparib]

    Source:
    FDA
    Test:

    BRACAnalysis CDx™, FoundationFocus CDxBRCA Assay

    Published date:
    12/19/2016
    Excerpt:
    RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-) associated advanced ovarian cancer who have been treated with two or more chemotherapies.